ClinicalTrials.gg
RecruitingNCT07189377CLEAR-HBVUpdated Nov 17, 2025

Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors

A Phase 4 interventional study of Entecavir and HBIG in Hepatitis B Virus (HBV) and Lung Transplant Recipient, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by University Health Network, Toronto · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing entecavir in Hepatitis B — 6 open to participants now, 9 under way, none of them phase 3. entecavir · Hepatitis B.

Planned enrollment
34th of 36
20 · median 106
Started
2025
the only one that year
Phase 4
20 of 37
5 open now
Registered
34th of 37
by date

Among the 37 studies testing entecavir in Hepatitis B, this one is the 34th largest by planned enrollment of the 36 interventional ones that give a count, is the only one that started in 2025, is one of 20 in phase 4, and was the 34th registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

6 of the 37 studies testing entecavir in Hepatitis B are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing entecavir in Hepatitis B, or all of them as a file.
02

Study summary

The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals

Read the detailed description

The success of transplantation is significantly hindered by the lack of sufficient available donors. Many potential donor organs are not fully utilized in clinical transplantation because donors have chronic viral infections. Currently, donors with chronic hepatitis B virus (HBV) infection are utilized by typically providing nucleoside analogues such as entecavir or lamivudine plus/minus several doses of HBIG. The entecavir or lamivudine are typically given either life-long in liver transplants or for 1 year in non-liver transplants. Donors with chronic HBV infection are Core Antibody positive (HBcAb +ve). These donors carry chronic virus but may be NAT positive or NAT negative. HBcAb+ve donors are routinely used, but NAT positive donors are typically not used. The Toronto lung transplant program commonly applies Ex Vivo Lung Perfusion (EVLP) to organs. This allows for treatment of organs prior to transplantation. The investigators have shown that UV light administered on the EVLP circuit can substantially decrease the amount of infectious virus. Such a strategy was previously employed with hepatitis C virus. The aim of the study is to show that transplantation of organs from HBV NAT+ve donors is safe with the use of UV light treatment on EVLP combined with post-transplant antivirals for the recipient (HBIG and entecavir). The investigators hypothesize that rates of HBV transmission to recipients will be prevented by the use of this approach and any HBV transmission that does occur will be readily treatable. This will be a small pilot study to determine the feasibility of this approach. If successful, the knowledge from this study can have an important impact on patients awaiting lung transplantation by providing a novel strategy for the use of HBV-positive organ donors, simplified through a shorter course of approved antivirals.

03

Conditions studied

  • Hepatitis B Virus (HBV)
  • Lung Transplant Recipient

Browse trials for

Keywords

  • HBV Disease
  • EVLP
  • lung transplant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Donor Inclusion Criteria

  • Donor lung suitable for transplantation
  • SAg positive and/or HBV NAT+ donor

Donor Exclusion Criteria

  • positive
  • HTLV 1/2 positive;
  • Any medical issues in the donor that would normally clinically exclude the donor (e.g. history of cancer, evidence of organ dysfunction, etc).

Recipient inclusion Criteria:

  • Recipients eligible and listed for lung transplant
  • HBV NAT negative
  • Provides written
  • Has received at least 3 prior doses of Hepatitis B vaccine or anti-HBs>=10 IU/mL
  • Patients with other co-morbid conditions (such as diabetes, disease, renal dysfunction) will remain eligible provided they are otherwise medically suitable for transplantation. The exception to this will be patients with significant liver disease as outlined below.

Recipient exclusion Criteria:

  • Chronic liver disease with > stage 2 fibrosis
  • Participating in another interventional clinical trial
  • Recipient listed for combined transplant (e.g., heart-lung, lung-liver)
  • Known allergy or to any of the antiviral medications
  • Hepatitis B surface antigen (HBsAg) or Hepatitis B core Ab positive pre-transplant (indicates already HBV infected).
  • HIV positive
  • Patients with a low level of serum IgA pre-transplant (this may be a risk factor for sensitivity reaction to HBIG).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    UV Light + Short-course Entecavir/HBIG

    Patients will receive lungs from HBV NAT+ donors, which will be treated with UV light therapy during ex-vivo perfusion. Patients will also receive Entecavir and HBIG prophylaxis in the immediate peri-operative period.

    Drug: Entecavir · Biological: HBIG · Device: EVLP UV Light Treatment

Interventions

  • Recipients will receive 1mg administered orally, beginning pre-transplant as soon as the patient arrives to the hospital for surgery, and then 1mg post-operatively administered orally or via nasogastric tube once daily for 28 days.

  • BiologicalHBIG

    Recipients will receive 4500 IU intravenously pre-transplant and then at day 3 and 7 post-transplant (3 doses total).

  • DeviceEVLP UV Light Treatment

    UV light therapy will be administered to the organ during EVLP prior to transplantation. For minimum 2 hours, maximum 6 hours (duration determined by time clinically required for EVLP based on standard clinical assessment of lung).

06

What researchers measure

Primary outcomes

  1. Safety of transplantation using HBV positive donors reflected by negative HBV NAT at 6 months post-transplant

    Participant blood samples will be taken at days 3 and 7, then weekly for the first 4 weeks, then every two weeks until 12 weeks post-transplant, then at month 6 after transplantation. Blood samples will be tested for HBV DNA via Nucleic Acid Amplification.

    Time frame: At 6 months post-transplant

Secondary outcomes

  1. Incidence of any HBV donor to recipient transmission

    Time frame: From enrollment until 2 years post-transplant

  2. Correlation between donor viremia level, and recipient infection

    Time frame: From enrollment until up to 2 years post-transplant

  3. Interval of time from transplantation to viremia development

    Time frame: From enrollment until 2 years post-transplant

  4. HBV suppression rates after treatment for infected patients

    Time frame: From time of infection until end of treatment or up to 2 years post-transplant

  5. Adverse reactions to antiviral therapy

    Time frame: From enrollment until 2 years post-transplant

  6. Incidence of acute liver dysfunction for infected patients

    Time frame: From enrollment until 2 years post-transplant

  7. In-hospital mortality

    Time frame: From hospital admission until date of discharge or date of death from any cause, whichever comes first, assessed up to 2 years

  8. 1-year graft and patient survival

    Time frame: Measured 1 year post-transplant

  9. Organ function at 1 year (FEV1)

    Time frame: Measured 1 year post-transplant

  10. Development of anti-HBV antibodies (anti-HBs, anti-HBc)

    Time frame: From enrollment until 2 years post-transplant

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Aug 2027, 23 months after the start.

Of 47 non-industry phase 4 interventional studies under Hepatitis B, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 66. This study's planned 23 months is below that.

Counting every sponsor, half of 63 studies reached it within 35 months; a quarter within 12 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Sep 23, 2025
StartActual
Sep 24, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07189377
Responsible party
Sponsor
First posted
Sep 23, 2025
Start date
Sep 24, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

Atul Humar, MD, FRCPC
Contact
atul.humar@uhn.ca
416-340-4241

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Entecavir · Hepatitis B hyperimmune globulin

Start the discussion